Data from the LEADLESS II study also highlighted the St. Jude Medical Nanostim leadless pacemaker’s retrievability, projected longevity and the promising future of leadless pacing
ST. PAUL, Minn. & LONDON--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced primary results from the LEADLESS II study that confirm the positive benefits of the Nanostim™ leadless pacemaker for patients in need of a single-chamber ventricular pacemaker. The study also demonstrated the Nanostim leadless pacemaker’s longer-term retrievability and the device’s significant projected battery longevity.
Help employers find you! Check out all the jobs and post your resume.
